Compare KRMD & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | TNYA |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 168.2M |
| IPO Year | 2019 | 2021 |
| Metric | KRMD | TNYA |
|---|---|---|
| Price | $3.40 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $6.50 | $5.33 |
| AVG Volume (30 Days) | 229.6K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.85 | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $20.32 | N/A |
| Revenue Next Year | $17.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $3.21 | $0.53 |
| 52 Week High | $6.61 | $2.35 |
| Indicator | KRMD | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 43.86 |
| Support Level | $3.21 | $0.65 |
| Resistance Level | $4.27 | $0.81 |
| Average True Range (ATR) | 0.22 | 0.04 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 12.72 | 12.91 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.